General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Anti-Aging
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

New Data on Investigational Tralokinumab for Treatment of AD

Name: New Data on Investigational Tralokinumab for Treatment of AD
Uploaded: 2021-10-13T11:38:00.000Z
Description: In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

October 13, 2021

Linda Stocum, Associate Editor

Video

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, a dermatologist and president of Oregon Medical Research Center in Portland, Oregon, discusses the newest phase 3 clinical data on tralokinumab (LEO Pharma).

Tralokinumab is an investigational monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of atopic dermatitis (AD) and is currently being evaluated by the FDA. Hear what he has to say about the newest data from the ECZTEND (NCT03587805) trial in the video below.